Qrem is a technology company.
Qrem has raised $1.0M across 1 funding round.
Qrem has raised $1.0M in total across 1 funding round.
Qrem has raised $1.0M in total across 1 funding round.
Qrem's investors include Inveready Technology Investment Group.
Qrem (Tecnología Regenerativa Qrem, SL) is a Barcelona-based biotech company founded in 2016 that develops the Qrem Cytokine, a lab-in-a-box medical device for autologous regenerative therapies targeting knee osteoarthritis (OA) and other musculoskeletal conditions[1][2][3][4][6]. The device processes a patient's blood in 30 minutes at the point of care to produce a Cytokine Rich Serum (CRS)—rich in anti-inflammatory cytokines and growth factors—for intra-articular injection, achieving up to 75% pain reduction lasting over a year in preliminary studies[1][2][4]. It serves orthopedic doctors and patients suffering from OA progression, solving the need for natural, non-invasive treatments that restore joint balance without surgery or long-term drugs, while enabling in-office autonomy and reducing preservation risks for biologics[2][4].
With a small team of 1-10 employees, Qrem has secured funding from investors like Inveready and Ship2B, and holds a medical device license (7096-PS) from Spain's AEMPS, positioning it as a pioneer in automated, sterile regenerative tech[2][4][5].
Qrem emerged as a spin-out from Sener, a multinational engineering firm, after three years of internal R&D on regenerative health tech that Sener chose not to pursue commercially[1]. Founders Josep Maria Escuer (CEO, business development lead) and Núria Noguera (R&D Director, product development expert since 2005 at Sener) licensed the project and formally constituted Tecnología Regenerativa Qrem on July 25, 2016, in Barcelona, Spain[1][2][4]. Núria had long championed in-house health product development at Sener, while Josep Maria brought leadership and adaptability; they bootstrapped with a committed, altruistic extended team from their Sener days, navigating resource constraints and the shift from corporate to startup ecosystems[1].
Early challenges included adapting to lean operations without multinational backing and learning investor networks, but pivotal traction came from preliminary studies validating 75% pain relief, fueling their bet on the tech's potential[1][2].
Qrem stands out in regenerative medicine through these key strengths:
Qrem rides the regenerative medicine wave, capitalizing on rising demand for autologous therapies amid aging populations and OA prevalence (affecting millions globally with limited non-surgical options)[2][4][6]. Timing aligns with advances in point-of-care biotech, where lab-in-a-box automation addresses scalability gaps in personalized medicine—reducing costs, wait times, and lab dependency versus centralized processing[3][4]. Favorable market forces include regulatory nods (e.g., AEMPS approval) and investor interest in healthtech spin-outs, amplified by post-pandemic emphasis on in-office, low-risk treatments[1][2][4]. Qrem influences the ecosystem by democratizing advanced biologics for clinicians, potentially accelerating adoption of cytokine-rich therapies and inspiring similar devices for other degenerative diseases[1][6].
Qrem's compact, efficacious platform positions it for expansion into full commercialization and new indications like other joints or chronic inflammation, leveraging its investor backing and clinical data[2][4]. Trends like AI-driven personalization in regen med and global OA burden (projected to surge with demographics) will propel growth, especially if partnerships with orthopedics firms scale distribution. Its influence may evolve from niche innovator to ecosystem enabler, powering accessible natural therapies—echoing its origins as a bold spin-out tackling unmet knee health needs with lab-in-a-box precision[1][6].
Qrem has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $1.0M Seed | Inveready Technology Investment Group |